The Official Website of the Long-Term Investor
Results 1 - 10 of 984 : 1 2 3 4 5 6 7 8 9 Next
Get RSS Feed for Major 2006 Lawsuit
Have J&J's Approval Hopes Vanished?
Johnson & Johnson might have trouble sidestepping the competition.
The Meaningless Drug Approval That Could Cost the Industry Billions
Being able to use surrogate endpoints is important for drug developers.
5 Pharmaceutical Stocks With Significant Exposure to Europe
A fracture of the European monetary union could spell trouble for these five pharmaceutical stocks.
The Dow Couldn't Hold Back These 4 Stocks
These Dow stocks bucked a down market.
This Biotech's for Sale! Reportedly.
Bloomberg reports on Amylin's potential suitors.
FDA advisory panel recommends approving rheumatoid arthritis drug tofacitinib.
Rheumatoid arthritis drug tofacitinib could be a blockbuster.
What Could Move the Markets Today
A brief on the upcoming market news for May 1.
Another Reason to Get Excited About VIVUS
VIVUS gets its new erectile dysfunction drug Stendra approved.
1 Unexcitingly Good Dividend Play
Merck has slow growth, but that's OK.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK